Keith F. McDaniel

The University of Texas MD Anderson Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index2.2kcitations151works0.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(106), Multiple Myeloma Research and Treatments(86), HIV/AIDS drug development and treatment(25), CAR-T cell therapy research(25), Ubiquitin and proteasome pathways(23)

Publications150 total

Data from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

2023Open Access

Data from HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues

2023Open Access

Data from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

2023Open Access

Supplemental Figure 1 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

2023Open Access

Figure S5 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

2023Open Access

Supplemental Figures 1-4; Supplemental Tables 2,4,5 from HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues

2023Open Access

Table S1 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

2023Open Access

Figure S2 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

2023Open Access

Figure S4 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

2023Open Access

Supplemental Figure 6 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

2023Open Access

Supplemental Table 3 from HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues

2023Open Access

Figure S4 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

2023Open Access

Figure S5 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

2023Open Access

Supplemental Figure 4 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

2023Open Access

Supplemental Figure 2 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

2023Open Access

Supplemental Figure 6 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

2023Open Access

Figure S1 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

2023Open Access

Supplemental Figure 2 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

2023Open Access

Figure S3 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

2023Open Access

Supplemental Table 1 from HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues

2023Open Access

page 1 of 8Next →

Frequent Co-authors

Warren M. Kati(20), Daniel H. Albert(16), Yu Shen(16), Dale J. Kempf(15), Xiaoli Huang(11), John K. Pratt(11), Dachun Liu(11), Emily J. Faivre(10), Denise Wilcox(10), Tamar Uziel(10), Akhteruzzaman Molla(10), Mai H. Bui(9), Paul Hessler(9), George S. Sheppard(8), Lisa Hasvold(8), Clarence J. Maring(8), Xiaoyu Lin(7), Leiming Li(7), Terrance J. Magoc(7), Lloyd T. Lam(6)